IN2014CN03493A - - Google Patents
Download PDFInfo
- Publication number
- IN2014CN03493A IN2014CN03493A IN3493CHN2014A IN2014CN03493A IN 2014CN03493 A IN2014CN03493 A IN 2014CN03493A IN 3493CHN2014 A IN3493CHN2014 A IN 3493CHN2014A IN 2014CN03493 A IN2014CN03493 A IN 2014CN03493A
- Authority
- IN
- India
- Prior art keywords
- heterocyclic group
- divalent heterocyclic
- substituted
- ring
- cycloalkylene
- Prior art date
Links
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 2
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 abstract 1
- QBXNXHODSIQDRT-AWEZNQCLSA-N 2-[2-[2-[[(2s)-4-[(3,4-dichlorophenyl)methyl]morpholin-2-yl]methylamino]-2-oxoethyl]sulfanyl-1,3-thiazol-4-yl]acetic acid Chemical compound OC(=O)CC1=CSC(SCC(=O)NC[C@@H]2OCCN(CC=3C=C(Cl)C(Cl)=CC=3)C2)=N1 QBXNXHODSIQDRT-AWEZNQCLSA-N 0.000 abstract 1
- -1 MORPHOLINE COMPOUND Chemical class 0.000 abstract 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
ABSTRACT MORPHOLINE COMPOUND The present invention relates to a compound represented by the formula (1) (°)m ° System.Environment.newline/m II Z-YX®^,CH2)n^N-^N^) wherein ring A is aryl, or substituted aryl, ring B is divalent heterocyclic group, substituted divalent heterocyclic group, C3_8 cycloalkylene or substituted C3_8 cycloalkylene wherein the divalent heterocyclic group is thienyl, furyl, thiazolyl, 1,3,4- thiadiazolyl, pyridyl, pyridazinyl or pyrazinyl, or a partially hydrogenated ring group thereof, m is an integer of 0 to 2,n is an integer of 1 to 5, X is a bond and the like;Y is a bond and the like; And Z is hydrogen atom and the like ; provided that (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{ [4- (3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide is excluded,or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004261655 | 2004-09-08 | ||
PCT/JP2005/017002 WO2006028284A1 (en) | 2004-09-08 | 2005-09-08 | Morpholine compound |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014CN03493A true IN2014CN03493A (en) | 2015-07-03 |
Family
ID=36036551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN3493CHN2014 IN2014CN03493A (en) | 2004-09-08 | 2005-09-08 |
Country Status (13)
Country | Link |
---|---|
US (1) | US7935700B2 (en) |
EP (1) | EP1801108B9 (en) |
JP (1) | JP4970946B2 (en) |
KR (1) | KR101011848B1 (en) |
CN (1) | CN101014580B (en) |
CA (1) | CA2579207C (en) |
DK (1) | DK1801108T3 (en) |
ES (1) | ES2396419T3 (en) |
IN (1) | IN2014CN03493A (en) |
PL (1) | PL1801108T3 (en) |
PT (1) | PT1801108E (en) |
TW (1) | TW200619212A (en) |
WO (1) | WO2006028284A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006082030A1 (en) * | 2005-02-04 | 2006-08-10 | Ctg Pharma S.R.L. | New 4-aminoquinoline derivatives as antimalarials |
KR101386494B1 (en) | 2005-05-10 | 2014-04-24 | 인사이트 코포레이션 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
JP5294874B2 (en) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | N-hydroxyamidino heterocycle as modulator of indoleamine 2,3-dioxygenase |
EP2042499B1 (en) * | 2006-07-11 | 2018-06-27 | Mitsubishi Tanabe Pharma Corporation | Salt of a morpholine compound |
WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
CL2007002650A1 (en) * | 2006-09-19 | 2008-02-08 | Incyte Corp | COMPOUNDS DERIVED FROM HETEROCICLO N-HIDROXIAMINO; PHARMACEUTICAL COMPOSITION, USEFUL TO TREAT CANCER, VIRAL INFECTIONS AND NEURODEGENERATIVE DISORDERS BETWEEN OTHERS. |
WO2008036652A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
WO2008123582A1 (en) | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | Tetrahydroisoquinoline compound |
KR101649548B1 (en) | 2008-07-08 | 2016-08-19 | 인사이트 홀딩스 코포레이션 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
WO2015012332A1 (en) * | 2013-07-24 | 2015-01-29 | 田辺三菱製薬株式会社 | Therapeutic agent for ophthalmic disease |
MX366874B (en) | 2013-11-08 | 2019-07-29 | Incyte Holdings Corp | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor. |
WO2020203822A1 (en) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | Combined drug for treating or preventing retinal disease associated with angiogenesis |
EP4021898A1 (en) * | 2019-08-26 | 2022-07-06 | Stichting VUmc | Inhibition of mycobacterial type vii secretion |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
JPS63264467A (en) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | Benzamide derivative |
JPH03148276A (en) * | 1989-11-01 | 1991-06-25 | Yoshitomi Pharmaceut Ind Ltd | Optically active pyridonecarboxylic acid compound |
AU1208397A (en) | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
AU729415B2 (en) | 1996-07-12 | 2001-02-01 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
AU5522498A (en) | 1996-12-13 | 1998-07-03 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
WO1999055330A1 (en) | 1998-04-27 | 1999-11-04 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
BR9915735A (en) | 1998-11-20 | 2001-09-04 | Hoffmann La Roche | Piperidine ccr-3 receptor antagonists |
WO2000034278A1 (en) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as the active ingredient |
WO2000053600A1 (en) * | 1999-03-11 | 2000-09-14 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
BR0009338A (en) | 1999-03-26 | 2001-12-26 | Astrazeneca Ab | Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and method of treating an inflammatory disease in a patient suffering or at risk of said disease |
SE9902987D0 (en) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
PL362984A1 (en) | 2000-09-29 | 2004-11-15 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
CN1678594A (en) * | 2000-09-29 | 2005-10-05 | 葛兰素集团有限公司 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
CA2445348A1 (en) | 2001-04-27 | 2002-11-07 | Mitsubishi Pharma Corporation | Novel benzylpiperidine compound |
GB0207445D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207443D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0208158D0 (en) | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
GB0207439D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0212355D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
PL375263A1 (en) * | 2002-07-02 | 2005-11-28 | F.Hoffmann-La Roche Ag | 2,5-substituted pyrimidine derivatives as ccr-3 receptor antagonists |
-
2005
- 2005-09-08 JP JP2006535186A patent/JP4970946B2/en not_active Expired - Fee Related
- 2005-09-08 ES ES05783689T patent/ES2396419T3/en active Active
- 2005-09-08 PT PT57836892T patent/PT1801108E/en unknown
- 2005-09-08 US US11/662,228 patent/US7935700B2/en not_active Expired - Fee Related
- 2005-09-08 CA CA2579207A patent/CA2579207C/en not_active Expired - Fee Related
- 2005-09-08 CN CN2005800301370A patent/CN101014580B/en not_active Expired - Fee Related
- 2005-09-08 PL PL05783689T patent/PL1801108T3/en unknown
- 2005-09-08 KR KR1020077007863A patent/KR101011848B1/en active IP Right Grant
- 2005-09-08 EP EP05783689.2A patent/EP1801108B9/en active Active
- 2005-09-08 IN IN3493CHN2014 patent/IN2014CN03493A/en unknown
- 2005-09-08 WO PCT/JP2005/017002 patent/WO2006028284A1/en active Application Filing
- 2005-09-08 TW TW094130939A patent/TW200619212A/en not_active IP Right Cessation
- 2005-09-08 DK DK05783689.2T patent/DK1801108T3/en active
Also Published As
Publication number | Publication date |
---|---|
JP4970946B2 (en) | 2012-07-11 |
WO2006028284A1 (en) | 2006-03-16 |
TWI367209B (en) | 2012-07-01 |
ES2396419T3 (en) | 2013-02-21 |
DK1801108T3 (en) | 2013-02-18 |
PL1801108T3 (en) | 2013-04-30 |
EP1801108A1 (en) | 2007-06-27 |
US7935700B2 (en) | 2011-05-03 |
CA2579207C (en) | 2011-10-18 |
TW200619212A (en) | 2006-06-16 |
EP1801108B1 (en) | 2012-11-14 |
JPWO2006028284A1 (en) | 2008-05-08 |
KR101011848B1 (en) | 2011-02-01 |
EP1801108B9 (en) | 2013-11-20 |
US20070265257A1 (en) | 2007-11-15 |
KR20070099528A (en) | 2007-10-09 |
CN101014580B (en) | 2011-05-04 |
CA2579207A1 (en) | 2006-03-16 |
CN101014580A (en) | 2007-08-08 |
EP1801108A4 (en) | 2010-10-13 |
PT1801108E (en) | 2012-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014CN03493A (en) | ||
MX2009012283A (en) | Nitrogen-containing heterocyclic derivative having 11 î²-hydroxysteroid dehydrogenase type i inhibitory activity. | |
CA2316902A1 (en) | Alpha-aminoamide derivatives useful as analgesic agents | |
JP2006521359A5 (en) | ||
MY145408A (en) | Dihydropyrazolopyrimidinone derivatives | |
EP1798226A4 (en) | Triazole derivative | |
IL189069A0 (en) | Piperidine and piperazine derivatives as p2x3 antagonists | |
TW200605883A (en) | Condensed heterocycle derivative having HCV inhibitory activity | |
SG160195A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
TW200745034A (en) | New compounds | |
NO20052993L (en) | 4,5-diarylthiazole derivatives as CB-1 ligands. | |
EP1533292A4 (en) | Dibenzylamine compound and medicinal use thereof | |
JO2791B1 (en) | Acid secretion inhibitor | |
UA83243C2 (en) | Compounds having inhibitory activity against sodium-dependant transporter | |
NZ590355A (en) | Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient | |
EP1642880A4 (en) | Hsp90 family protein inhibitors | |
AU2003254852A8 (en) | Fused heterocyclic compounds as peptidase inhibitors | |
TW200726470A (en) | 6,7-unsaturated-7-carbamoylmorphinan derivatives | |
DE69505968D1 (en) | AZOLIDINDION DERIVATIVES AND THEIR USE AS ANTI-HYPERGLYCEMAS | |
WO2008136444A1 (en) | Fused heterocyclic derivative | |
WO2004017977A3 (en) | 2- (phenoxymethyl)- and 2- (phenylthiomethyl)-morpholine derivatives for use as selective norepinephrine reuptake inhibitors | |
TW200503712A (en) | (2-carboxamido)(3-amino)thiophene compounds | |
WO2008153042A1 (en) | Anti-tumor agent | |
TW200510361A (en) | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives | |
WO2005061475A3 (en) | Ornithine derivatives as prostaglandin e2 agonists or antagonists |